In an effort to improve survival and reduce late adverse effects of radiation therapy (RT), 25 children o3 years of age with malignant brain tumors received tandem high-dose chemotherapy (HDCT) and auto-SCT following six cycles of induction chemotherapy. RT was either not given or deferred until 3 years of age if the patient was in CR after tandem HDCT/auto-SCT. Tumors relapsed or progressed in nine patients (five during induction treatment), and two of these patients survived after receiving salvage treatment, including RT. Two patients died due to toxicities during tandem HDCT/auto-SCT. A total of 16 patients survived to a median follow-up period of 52 months (range 18-96) from the time of diagnosis. Four of these patients did not receive RT, two received local RT (L-RT), three received craniospinal RT (CSRT), and seven received both L-RT and CSRT. The 5-year OS and EFS rates were 67.8 ± 9.4% and 55.5 ± 10.0%, respectively. Neuroendocrine and neurocognitive functions evaluated 3 years after tandem HDCT/auto-SCT were acceptable. Our results indicate that tandem HDCT/auto-SCT may improve survival in young children with malignant brain tumors with an acceptable level of risk of long-term toxicity.
INTRODUCTION
Treatment of malignant brain tumors in young children is challenging, as radiation therapy (RT) is used minimally due to the risk of functional impairment of the developing brain, and late adverse effects, including global reduction in the intelligence quotient, cognitive deficits, and neuroendocrine dysfunction. [1] [2] [3] [4] In an effort to minimize these effects, a number of institutions and national groups have adopted chemotherapy-based strategies designed to avoid or delay RT, though outcomes have been largely unsatisfactory. [5] [6] [7] A treatment strategy that uses high-dose chemotherapy (HDCT) and auto-SCT has helped to improve the prognosis of recurrent or high-risk solid tumors in children. [8] [9] [10] Clinical trials using HDCT/auto-SCT for treatment of infants and young children with malignant brain tumors have shown that it is possible to avoid or defer RT until 3 years of age while maintaining or improving survival rates. [11] [12] [13] Additionally, several recent studies have suggested that dose-escalation using tandem HDCT/auto-SCT might further improve outcomes in the treatment of recurrent or high-risk brain tumors. 14, 15 In the present study, we prospectively evaluated the feasibility and effectiveness of tandem HDCT/auto-SCT in children o3 years of age with malignant brain tumors. RT was either not given or deferred until 3 years of age if the patient achieved CR after tandem HDCT/auto-SCT. Local RT (L-RT) was given only if gross residual tumor (41.5 cm 2 ) remained after surgery, and craniospinal RT (CSRT) was given only if leptomeningeal seeding was present at the time of diagnosis. This new treatment strategy aimed to simultaneously improve survival and reduce the risk of significant late adverse effects of RT.
PATIENTS AND METHODS Patients
Children o3 years of age diagnosed with malignant brain tumors between September 2004 and March 2011 were eligible for enrollment in our study. A pediatric neuropathologist reviewed all cases according to the World Health Organization criteria. The extent of disease at the time of diagnosis was assessed using brain and spinal magnetic resonance imaging and cerebrospinal fluid cytology. The Samsung Medical Center Institutional Review Board approved this study, and informed consent was obtained from all the parents or guardians.
Induction treatment before HDCT/auto-SCT Figure 1 shows the treatment scheme used in this study. Surgery was the primary treatment for all resectable tumors. Second-look surgery was performed whenever possible. Six cycles of induction chemotherapy were administered before HDCT/auto-SCT, consisting of alternating CECV (cisplatin þ etoposide þ cyclophosphamide þ vincristine) and CEIV (carboplatin þ etoposide þ ifosfamide þ vincristine) regimens (Table 1) . Each induction chemotherapy cycle was scheduled to be 28 days apart, but some delays were permitted to allow for recovery of the ANC and platelet count to 1.0 Â 10 9 /l and 100 Â 10 collected during a single round of leukapheresis were infused for marrow rescue during each HDCT/auto-SCT session.
RT
RT was either not given or was deferred until 3 years of age if the patient achieved CR after tandem HDCT/auto-SCT. Use of RT was determined according to the tumor status at the time of diagnosis. L-RT (30.6 Gy, 1.8 Gy/fraction) was given after the patient reached 3 years of age only if gross residual tumor (41.5 cm 2 ) remained after initial or second-look surgery. For L-RT to the primary site, the radiation target volume was not the entire posterior fossa but rather the surgical defect with 1-2 cm margins. This L-RT to the primary site was performed by three-dimensional conformal RT. CSRT (23.4 Gy, 1.8 Gy/fraction) was given after the patient reached 3 years of age only if leptomeningeal seeding was present at the time of diagnosis. If the patient had not achieved CR after tandem HDCT/auto-SCT, both L-RT and CSRT were immediately given. In one patient with anaplastic ependymoma (AE), L-RT was given for persistent residual tumor at the primary site after tandem HDCT/auto-SCT.
Response and toxicity criteria Disease response was evaluated by the brain and spinal magnetic resonance imaging and cerebrospinal fluid cytology after the second, fourth, and sixth induction chemotherapy cycles preceding HDCT/auto-SCT, between the first and second HDCT/auto-SCT, every 3 months for the first year after completion of HDCT/auto-SCT, every 4 months for the second year, and every 6 months thereafter. Tumor size was estimated by magnetic resonance imaging as the product of the greatest diameter and the longest perpendicular diameter. Disease response was categorized as follows: progressive disease (PD), 425% increase in tumor size or the appearance of a new tumor; stable disease, o25% change in tumor size; minor response, a 25-50% decrease in tumor size; PR, 450% decrease in tumor size; and CR, complete disappearance of all previously measurable tumor. Toxicities were graded using the National Cancer Institute's Common Terminology Criteria (version 4.0).
Evaluation of late adverse effects
Late adverse effects were evaluated yearly after completion of the second HDCT/auto-SCT. The diagnosis of growth hormone deficiency was based on a declining growth rate as well as biochemical confirmation. Hypothyroidism was diagnosed in cases of elevated thyrotropin. The diagnosis of adrenal insufficiency was based on failure to increase serum cortisol after administration of corticotropin-releasing hormone. Cognitive function was evaluated using the Korean-Wechsler Preschool and Primary Scale of Intelligence. Cardiac, renal, hepatic, auditory, ophthalmologic, and immune functions were also evaluated.
Statistics
EFS was determined from the date of diagnosis to the date of relapse, progression, or death (whichever occurred first). OS was determined from the date of diagnosis to death from any cause. Survival rates and s.es. were estimated using the Kaplan-Meier method. Differences in the survival rates between the groups were compared using log-rank tests. P-values o0.05 were considered to be statistically significant.
RESULTS

Patient characteristics
Twenty-five consecutive patients (12 boys and 13 girls) with malignant brain tumors, including 8 medulloblastomas (MBs), Figure 1 . Treatment scheme. Surgery was the primary treatment for all resectable tumors. Six cycles of conventional induction chemotherapy were administered before HDCT/auto-SCT. CECV and CEIV regimens were used in alternation. CTE and CM regimens were used for the first and second HDCT, respectively. If the patient was not in CR after tandem HDCT/auto-SCT, both L-RT and craniospinal RT were immediately given. If the patient was in CR after tandem HDCT/auto-SCT, RT was not given or was deferred until 3 years of age. The type of RT given was determined according to the tumor status at the time of diagnosis (Dx). L-RT (30.6 Gy, 1.8 Gy/fraction) was given after 3 years of age only if gross residual tumor (41.5 cm 2 , R þ ) remained after initial or second-look surgery. CSRT (23.4 Gy, 1.8 Gy/fraction) was given after 3 years of age only if leptomeningeal seeding was present at the time of diagnosis (M þ ). However, RT was not given to patients who had neither gross residual tumor after surgery nor leptomeningeal seeding at the time of diagnosis (R0 M0).
3 primitive neuroectodermal tumors, 5 atypical teratoid/rhabdoid tumors (ATRTs), 6 AEs, 2 glioblastoma multiformes, and 1 malignant fibrous histiocytoma were enrolled in this study. Patient characteristics are shown in Table 2 . The median age at the time of diagnosis was 15 months (range 1-35). Seventeen patients had significant residual tumor (41.5 cm 2 ) after initial surgery, and leptomeningeal seeding was present at the time of diagnosis in 18 patients.
Induction treatment Induction chemotherapy was successfully administered without significant organ toxicity, though all patients experienced neutropenic fever. The median number of CD34 þ cells collected during three leukapheresis events was 55.5 Â 10 6 cells/kg (range 2.3-244.9). Five patients experienced PD during induction treatment. In one patient, a gross total resection of the tumor was performed following six cycles of induction chemotherapy.
All 20 patients who remained progression-free during induction treatment proceeded to the first HDCT/auto-SCT and their tumor statuses were CR in 7 patients and PR in 13 patients. One of the five patients who experienced PD during induction treatment also proceeded to HDCT/auto-SCT after second-look surgery (Figure 2 ).
Tandem HDCT/auto-SCT The median age at the first HDCT/auto-SCT was 23 months (range 7-43). The median time from the first infusion of PBSCs to the initiation of the second HDCT/auto-SCT was 83 days (range 74-127). Second-look surgery was performed after the first HDCT/auto-SCT in one patient. Table 3 shows the characteristics of tandem HDCT/auto-SCT. Neutrophil and platelet counts recovered rapidly during both the first and second HDCT/auto-SCT. Frequent grade 3/4 toxicities during the first HDCT/auto-SCT included fever, stomatitis, diarrhea, elevation of liver enzymes, and hypokalemia. One patient died from hepatic veno-occlusive 
RT
One patient began RT after two cycles of induction chemotherapy due to PD, but this treatment was not completed due to further progression during RT. Only five patients who had achieved PR after tandem HDCT/auto-SCT (n ¼ 4), or had experienced PD after the second HDCT/auto-SCT (n ¼ 1), received RT immediately after the second HDCT/auto-SCT (Figure 2) . Four of these patients received both CSRT and L-RT, and one patient received only L-RT. In the 13 patients who remained in CR until 3 years of age, RT was either deferred until after 3 years of age (n ¼ 9) or was not given (n ¼ 4). Overall, 15 patients received RT (L-RT alone in 3, CSRT alone in 4, and both L-RT and CSRT in 8 patients). The median age at the time of RT was 39 months (range 24-48). Among the 16 survivors, 4 patients received no RT, 2 received L-RT alone, 3 received CSRT alone, and 7 received both L-RT and CSRT. RT was initiated before 3 years of age in 3 of 16 survivors.
Survival
Tumors relapsed or progressed in nine patients (five during induction treatment and four after tandem HDCT/auto-SCT), two of which survived after receiving salvage treatment, including RT. Two patients died from toxicities during tandem HDCT/auto-SCT ( Figure 2 ). A total of 16 patients remained alive at a median followup period of 52 months (range 18-96) from the time of diagnosis. The 5-year OS and EFS rates were 67.8 ± 9.4% and 55.5 ± 10.0%, respectively (Figure 3a) . Table 4 shows survival rates with respect to clinical characteristics. The 5-year OS and EFS rates were higher in M0 patients than in M þ patients (OS 100 vs 55.0 ± 11.9%, P ¼ 0.022; EFS 85.7 ± 13.2% vs 43.2 ± 11.9%, P ¼ 0.078). The survival rates for the 5 ATRT patients were disappointing due to early progression of disease (5-year OS and EFS: 20.0±17.9% and Figure 2 . Flow of patients. Twenty-five consecutive patients with malignant brain tumors were enrolled in this study. All 20 patients who remained progression free during induction treatment proceeded to the first HDCT/auto-SCT, 7 of which achieved CR and 13 achieved PR. There was tumor progression during induction treatment in five patients, and one of these patients also proceeded to HDCT/auto-SCT after second-look surgery. Five patients received RT immediately after the second HDCT/auto-SCT, because they remained in PR after tandem HDCT/auto-SCT (n ¼ 4) or experienced PD after the second HDCT/auto-SCT (n ¼ 1). Tumors relapsed or progressed in nine patients (five during induction treatment and four after tandem HDCT/auto-SCT), two of whom survived after salvage treatment, including RT. Two patients died from toxicities during tandem HDCT/auto-SCT. A total of 16 patients survived. TRM, treatment-related mortality; REL, relapse; off-Tx, off treatment. The first day when ANC exceeded 0.5 Â 10 9 /L for 3 consecutive days. Tandem HDCT/auto-SCT for brain tumors in young children KW Sung et al 0%, respectively). However, the survival rates of the remaining patients with malignant brain tumors other than ATRT were encouraging (5-year OS and EFS: 80.0±8.9% and 69.6±10.4%, respectively) (Figures 3b and c) . Six of 8 MB patients, 2 of 3 primitive neuroectodermal tumor patients, 5 of 6 AE patients, 1 of 2 glioblastoma multiforme patients, and 1 malignant fibrous histiocytoma patient remained alive.
Late adverse effects Ten patients who remained event free for 43 years after the second HDCT/auto-SCT were evaluated for various late adverse effects (Table 5) . Frequent late adverse effects included hypothyroidism, growth hormone deficiency, hearing loss, and renal tubulopathy. Until 3 years after tandem HDCT/auto-SCT, a prominent deceleration in vertical growth was observed. The median height at 3 years after the second HDCT/auto-SCT was À 2.5 s.ds. from the mean (range from 0.2 to À 4.8) height with respect to patient age. The median values for full-scale, verbal, and performance intelligence quotient evaluated at a median follow-up period of 45 months (range 35-70) after the second HDCT/auto-SCT were found to be 75 (range 67-90), 83 (range 61-112), and 71 (range 69-86), respectively.
DISCUSSION
In the present study, we prospectively evaluated the use of tandem HDCT/auto-SCT in children with malignant brain tumors, aiming to both improve survival and avoid or defer RT until after the most radiosensitive neurodevelopmental milestones. Our results suggest that treatment with tandem HDCT/auto-SCT is feasible and may improve survival with acceptable rates of longterm toxicity.
We found that patients tolerated induction chemotherapy well, without prolonged cytopenia sufficient to delay chemotherapy. All patients did experience neutropenic fever; however, no significant organ toxicity occurred during induction chemotherapy. Toxicities experienced during the first HDCT/auto-SCT were generally tolerable, although severe mucositis-related toxicity was difficult to manage. The frequency and severity of mucositis-related toxicity was much lower during the second HDCT/auto-SCT. Two patients died from toxicities during tandem HDCT/auto-SCT; however, we believe that this toxic death rate may be acceptable considering the otherwise poor outcomes seen in young children with malignant brain tumors.
Exclusion or reduction of RT has been associated with fewer late adverse effects but also lower survival rates in the treatment of young children with malignant brain tumors. In the Head Start I and II studies, patients received RT only if residual tumor remained at the time of HDCT/auto-SCT or if the tumor had relapsed after HDCT/auto-SCT. [11] [12] [13] In the present study, the use of RT was determined by the tumor status after initial surgery but not the tumor status after chemotherapy, including HDCT/auto-SCT. Therefore, 9 of 13 patients who were in CR after tandem HDCT/ auto-SCT received RT after 3 years of age according to the tumor status at the time of diagnosis (L-RT alone in 2, CSRT alone in 3, and both L-RT and CSRT in 4 patients). All these patients except 1 diagnosed with ATRT remained event free. Although some of these survivors may have remained in CR without RT, it remains unclear who should receive RT and at what dose and volume in order to prevent relapse in these patients. Further studies are needed to address these issues.
Tumor type is also an important factor to be considered in determining treatment strategies, including RT in young children with malignant brain tumors. In the present study, all patients received uniform treatment regardless of tumor type. Our results show that survival rates were reasonably good in cases of malignant brain tumors other than ATRT. Of note, survival rates of non-embryonic brain tumors, particularly AE, were encouraging. The prognosis in cases of ATRT was poor, however, as all five ATRT patients experienced early progression or relapse and only one survived after receiving RT before 3 years of age. These findings suggest that our strategy to avoid or defer RT until after 3 years of age may not be as useful in ATRT patients. Recent studies have shown that RT might be more efficacious than chemotherapy for ATRT patients, even in young children. 16, 17 Chi et al. 18 recently reported encouraging results of a single-arm trial for newly diagnosed ATRT patients, in which L-RT was administered during the early treatment period irrespective of age. Taken together, these findings suggest that our treatment strategy needs to be tailored according to the pathological diagnosis in young children with malignant brain tumors, particularly in cases of ATRT. The 5-year OS and EFS rates were 67.8 ± 9.4% and 55.5 ± 10.0%, respectively. The survival rates for the five ATRT patients were disappointing due to early disease progression. (b, c) However, the survival rates of the remaining patients with malignant brain tumors other than ATRT were encouraging. Six of 8 MB patients, 2 of 3 primitive neuroectodermal tumor (PNET) patients, 5 of 6 AE patients, 1 of 2 glioblastoma multiforme patients, and 1 malignant fibrous histiocytoma patient survived.
MB was the most common malignancy in the present study, and six of eight MB patients remained alive. These results are encouraging, although the number of patients studied was low. Rutkowski et al. 19 reported the results of a HIT-SKK'92 study in which intraventricular chemotherapy was introduced as a substitute for RT. In their study, treatment was completed without RT in children who achieved CR after 6 months of intensive chemotherapy, including high-dose MTX and intraventricular MTX. They reported that PFS rate was excellent, particularly for R0 M0 patients (5-year PFS 82%). These findings suggest that young patients diagnosed with MB without significant post-operative residual tumor and without leptomeningeal seeding can be cured without RT or HDCT/auto-SCT. It is notable, however, that outcomes were not satisfactory for patients with macroscopic metastasis (5-year PFS 33%). In our study, on the other hand, four of six MB patients with macroscopic metastases remained alive, with deaths due to PD and treatmentrelated mortality. Taken together, our treatment strategy may be a viable option for young children diagnosed with metastatic MB. Incorporation of high-dose MTX and intraventricular MTX into induction treatment can be considered in future studies in order to further improve outcomes and reduce the RT dose necessary to prevent relapse or progression.
Among the 16 survivors, 4 patients did not receive RT, 5 received L-RT alone or CSRT alone, and 7 received both L-RT and CSRT. In addition, RT was initiated before 3 years of age in 3 of 16 survivors. As a result, our small cohort of patients experienced an acceptable incidence of delayed adverse effects. Endocrine dysfunction was acceptable, and sensory neural hearing loss was mild. In addition, no major organ dysfunction was noted. The verbal intelligence of these patients, which is encouraging, will have a key role in their adjustment to daily life. These results are encouraging, because prevention of late adverse effects is a major consideration in treating very young children with malignant brain tumors.
In summary, our results suggest that tandem HDCT/auto-SCT is feasible and effective in young children with malignant brain tumors, and RT may be avoided or deferred until 3 years of age without compromising survival in cases of malignant brain tumors other than ATRT. Further studies are needed, however, to determine the optimal RT strategy in young children undergoing tandem HDCT/auto-SCT.
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